We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.
Roche (RHHBY) stock declines as the late-stage study evaluating tiragolumab plus Tecentriq fails to meet its co-primary endpoint of progression-free survival.